Experimental data have implicated intravenous lipids as being immunosuppressive, yet evidence that lipids are associated with an increase in clinically documented infections is sparse. A prospective trial conducted in patients with hematologic malignancies who were undergoing bone marrow transplantation compared the incidence of bacteremia and fungemia during the first month after the transplant. Patients (n = 512) were randomly assigned to receive 6-8% (low dose) or 25-30% (standard dose) of total daily energy as a 20% lipid emulsion. An adaptive randomization scheme stratified for treatments that might influence infection outcome (hematopoietic growth factors, fluconazole, graft-versus-host disease prophylaxis with steroids, pentoxifylline, intravenous immunoglobulin, and total body irradiation). The transplant type (autologous, related family donor, or unrelated donor) did not differ in distribution between treatment groups. Of the evaluable patients (n = 482), 55 patients in the standard-dose lipid group developed bacteremia or fungemia compared with 54 in the low-dose lipid group. The log-rank test comparing the time to first infection found no association between the incidence of bacteremia or fungemia and intravenous lipid (P = 0.95). Similar results were found when analyzed as intent-to-treat (P = 0.98), when bacterial or fungal infections at all sites were included (P = 0.94), and when the observation period was extended to 60 d (P = 0.58 for blood infections, P = 0.77 for infections at all sites). These data indicate that moderate amounts of intravenous lipid rich in linoleic acid are not associated with an increased incidence of bacterial or fungal infections in patients undergoing bone marrow transplantation and receiving total parenteral nutrition. Am J Clin Nutr 1998;67:927-33.
INTRODUCTION
Experimental findings that soybean-and safflower-based intravenous lipid emulsions depress phagocytosis and, in animal models, lead to increased mortality generated early concern about the use of these emulsions (1) (2) (3) (4) . Evidence in humans that intravenous lipids result in increased infectious morbidity has been lacking (5) . Nonetheless, reservations have remained about the effects of intravenous lipids on immune defenses, kindled by a case-control report of an increased risk of coagulase-negative staphylococcal bacteremia related to the use of lipid in neonates (6) , as well as by preliminary work at our institution (7) and elsewhere (8) that suggested an increased risk of infection among patients undergoing bone marrow transplantation who were receiving intravenous lipids. A prospective, randomized trial seemed warranted to test the hypothesis that the provision of lipid emulsions resulted in more infections among recipients of marrow grafts.
Intravenous lipids have been used routinely since the 1970s in marrow transplant patients requiring total parenteral nutrition (TPN). Lipid-free intravenous nutrition results in the rapid development of biochemical signs of essential fatty acid deficiency posttransplant (9) . The lipid dose required to maintain normal plasma and membrane fatty acid composition during marrow transplantation is unknown. One study suggested that even 5% of total energy as linoleic acid, which is significantly more than normal human requirements, may not maintain normal fatty acid profiles in marrow transplant patients receiving TPN (10) . Thus, to prevent essential fatty acid deficiency as well as to provide a concentrated energy source and to limit the potential hepatic consequences and hyperglycemic effect of excessive dextrose administration, it has been standard practice at the Fred Hutchinson Cancer Research Center to provide 25-30% of TPN energy as lipid.
The purpose of this study was to examine the association between intravenous lipids and infections in patients hospitalized for autologous or allogeneic marrow grafting. Specifically, we conducted a randomized clinical trial to assess the association between 6-8% (low dose) and 25-30% (standard dose) of total estimated energy needs as lipid and the incidence of bacterial and fungal infections. The primary endpoint was the incidence of first bacteremia or fungemia by hospital discharge or 30 d posttransplant, whichever came first. Secondary endpoints included the incidence of all first bacterial and fungal infections by hospital discharge or 30 and 60 d posttransplant, the association of intravenous lipid with subsequent infections in patients with an established blood infection, and the frequency and severity of essential fatty acid deficiency in patients receiving the two lipid doses.
SUBJECTS AND METHODS

Subjects
Patients were eligible to participate in the study if they were undergoing either autologous or allogeneic marrow transplantation for a diagnosis of hematologic malignancy. Patients were excluded if they were 1) histoincompatible by more than one human leukocyte antigen with their donor, 2) recipients of a second transplant, 3) allergic to lipid emulsions, 4) hypertriglyceridemic as defined by a fasting triacylglycerol concentration > 3.95 mmol/L (> 350 mg/dL), 5) provided a dose equivalent to > 100 g lipid emulsion in the preceding month, or 6) being treated for a culture-proven infection at the time of random assignment. There were no age restrictions. Informed consent was obtained from 512 patients in accordance with the Fred Hutchinson Institutional Review Board before the start of conditioning therapy.
Lipid treatment
Random assignment to lipid group occurred on day 3 of conditioning and was based on an adaptive randomization scheme that stratified for factors that might influence the incidence of infection (11): receiving pentoxifylline, fluconazole, graft-versus-host disease (GVHD) prophylaxis with steroids, conditioning regimens with total body irradiation, intravenous immunoglobulin, or recombinant hematopoietic growth factors. Two doses of lipid emulsion (20% Liposyn II; Abbott Laboratories, Chicago) were compared: 6-8% of total energy as a minimum dose to meet essential fatty acid requirements (low dose) and 25-30% of total energy according to institutional practice (standard dose). Energy requirements were estimated to be Ϸ1.5 times the basal energy needs in adults (12) and 1.6 times the basal needs in children (13) .
Oral energy intake was assessed daily by using a standard procedure and software (FOOD PROCESSOR II nutritional database; ESHA Research, Salem, OR). Nutritional counseling to promote maximal oral intake was provided by dietetic technicians and registered dietitians to all patients as part of routine care. Initiation of TPN, including lipids, dextrose, and amino acids, was standardized and occurred when oral energy intake fell below basal needs. The first 24 h of intravenous lipids was not considered an exposure period relevant to the study hypothesis.
Intravenous nutrition was provided such that oral and TPN energy together met estimated energy requirements at 1.5 ϫ basal needs throughout the study period, consistent with usual clinical practice. Patients in the low-dose group received dextrose in lieu of lipid energy as required to meet the total energy goal. Lipids were infused over 12 h in both groups and continued until oral energy intake exceeded 41.8 kJ/kg (10 kcal/kg) for 2 successive days. Dextrose and amino acids may or may not have been continued at the time of lipid termination, depending on the judgment of the clinical team. If patients developed lipemic serum or refractory hyperglycemia, such that lipid treatment was modified, patients were classified as treatment failures.
Serum glucose was maintained at < 11.1 mmol/L (< 200 mg/dL) by providing insulin as required in the dextrose and amino acid solution with sliding-scale coverage for patients with unstable or undetermined needs in accordance with standard practice guidelines. The clinical team determined when hyperglycemia in a study patient could not be managed safely with the low dose of lipid.
Infection prophylaxis
Gastrointestinal decontamination was attempted with oral vancomycin, gentamicin, paromomycin, and either fluconazole or nystatin at hospital admission to start conditioning (chemotherapy with or without total body irradiation) only for patients isolated in laminar air flow environments. The patients in laminar air flow environments were also served low-bacteria diets, whereas patients in standard reverse isolation were served a general hospital diet. Intravenous ceftazidime was initiated for all patients when the absolute neutrophil count fell below 0.5 ϫ 10 9 /L and discontinued when the count remained above 0.5 ϫ 10 9 /L for > 48 h and the patient was afebrile. For patients with > 3 d of persistent fever despite ceftazidime, amphotericin B was added if fungal infection was suspected. Blood cultures were obtained when a patient's temperature exceeded 38.3°C (oral) or three times weekly when the patient was receiving high-dose steroids.
Infections
The primary endpoint of bacteremia or fungemia required the occurrence of one or more positive blood cultures with any organism regardless of associated symptoms. Micrococci, streptomycetes, penicillia, or aerobic diphtheroids (other than those from group J-K corynebacteria) were considered laboratory contaminants.
The secondary endpoints included other sites of infection. Tissue histology was used in instances in which the culture was negative for any positive fluorescent antibody to legionella (or other organism-specific monoclonal antibody) or any septate or nonseptate hyphal elements. Secondary endpoints included the following definitions: 1) Cellulitis: either localized erythema or swelling plus a positive aspirate or biopsy culture of the area for an organism other than a coagulase-negative staphylococcus or local erythema and swelling associated with a single positive blood culture (or two or more positive blood cultures when the organism is a coagulase-negative staphylococcus) in the absence of a positive local culture.
2) Pneumonia: identification of an infectious pathogen by bronchial alveolar lavage (BAL) or in lung tissue. For BAL, bacterial cultures required moderate to many colonies of a single or predominant organism or a count of 10 8 cells/L of a single organism by quantitative culturing, or by the identification of legionella or mycobacterial species. For candida pneumonia, fungal cultures of BAL required moderate to many colonies of candida species or a count of 10 6 cells/L of pure candida. For aspergillus pneumonia, septate hyphal elements were required. Lung tissue from biopsy or autopsy was used to define pneumonia by using histology for aspergillus or culture for bacteria.
3) Esophagitis: histologic evidence of invasive hyphal elements. Bacterial esophagitis was excluded.
4) Infection of liver, spleen, kidneys, and brain: aspiration or biopsy evidence of infection.
5) Sterile closed space infection (eg, central nervous system, peritoneal, or pleural).
6) Central venous catheter infection: local erythema at the exit site with purulent drainage positive for a single or predominant organism or inflammation (including redness and tenderness) ≥ 1 cm up the line from the exit site or at any other point along the tract with an associated positive blood culture in the absence of a positive local site culture.
7) Urinary tract infection: a urine culture with 5 ϫ 10 4 colonies of a single organism with or without symptoms. Lactobacillus spp. were considered contaminants.
Laboratory data
Plasma concentrations of essential fatty acids were assayed by gas chromatography (14) 20 d posttransplant (both study groups) and 40 d posttransplant (low-dose group only) to ensure that essential fatty acid deficiency was not an untoward consequence in the low-dose group. Essential fatty acid deficiency was defined as a ratio of eicosatrienoic acid to arachidonic acid (triene:tetraene) > 0.2 (15) .
Serum glucose and absolute neutrophil count were assayed daily. Engraftment was defined as achieving an absolute neutrophil count of 0.5 ϫ 10 9 /L for 2 consecutive days.
Statistical analysis
All infection endpoints and related clinical variables were determined during the initial hospitalization for transplant. No data were gathered after hospital discharge or during subsequent hospitalizations. Several infection endpoints were identified for statistical analysis. The primary endpoint was the time to first bacteremia or fungemia by 30 d posttransplant or hospital discharge, whichever came first. Secondary endpoints were the time to first bacteremia or fungemia by 60 d posttransplant, the times to first bacterial or fungal infection at any site by 30 and 60 d posttransplant, and the rate of subsequent blood infections once a patient became infected. Patients with an infection identified after random assignment to a treatment up to the first 24 h on lipid treatment were considered in an intent-to-treat group and were included in an analysis of the primary endpoint and the rate of subsequent blood infections only. The association between the hazard of infection and lipid group was examined with the logrank test (16) . Patients who were discharged before 30 or 60 d, died, or were treatment failures were censored at the time of these events for purposes of the log-rank test. To assess the association of lipid treatment with subsequent blood infections, the subset of patients with more than one blood infection were included in a Cox regression analysis for multivariate failure data (17) . Statistical analyses were conducted with the SAS statistical program (version 6.06.01; SAS Institute, Cary, NC).
The associations between lipid group and engraftment, GVHD, relapse to 150 d posttransplant, and death to 60 and 150 d posttransplant were examined with the log-rank test. Patients who died before onset of engraftment, GVHD, or relapse were censored at the time of death.
To maintain a significance level at 0.05 and provide ≥ 80% power to detect a difference (two-sided log-rank test) in incidence of 10% for the primary endpoint, a sample size of 512 was calculated. The sample size estimation for the primary endpoint was based on a published rate of blood infections in the first month posttransplant of 25% for autologous patients (18) and 35-40% for allogeneic patients with histocompatible family donors (19) ; it was modified assuming a reduction in sepsis rates to 10-20% with the use of hematopoietic growth factors in approximately one-half of the patients. Treatment with recombinant granulocyte-macrophage colony-stimulating factor in autologous patients reduced blood infection rates to 17% in a prospective, randomized trial (18) and in allogeneic patients with unrelated donors to 8% compared with a historical control rate of 25% (18, 20) . One interim analysis on the primary endpoint was conducted when 50% of the anticipated number of bacteremias or fungemias had occurred. Differences were not considered significant unless the P value was < 0.0025 for the interim, with the significance level for the final analysis set at 0.0475. No adjustments for multiple comparisons were made.
RESULTS
Infection outcome
The characteristics of the 512 patients (n = 253 in the standard-dose group, n = 259 in the low-dose group) are described in Table 1 . No differences were observed in age, sex, type of transplant, diagnosis, and laminar air flow isolation. Nor were any differences observed in the distribution of treatment protocols included in the stratification scheme that may have influenced infection outcome. Thirty patients developed infections before they received 24 h of lipid therapy (13 in the standard-dose and 17 in the low-dose group) and were determined inevaluable. Among these 30 patients, there was no apparent difference in the distribution of patient characteristics between lipid groups.
There were eight treatment failures, four in each group. One patient receiving standard lipid developed lipemia 23 d after starting lipids. In three patients the low-lipid dose was contraindicated clinically because of refractory hyperglycemia at 8, 22, and 34 d, respectively, after starting lipids. Three patients were removed from the study by their physician (one in each group before starting lipids and one in the standard-dose group 12 d after starting lipids). One patient in the standard-dose group declined to participate after random assignment before starting lipids.
There was no association between lipid group and time to first blood infection by 30 d posttransplant when all 512 patients were included in an intent-to-treat analysis (P = 0.98). In each group, 63 patients experienced a bacteremia or fungemia before 30 d. When only the evaluable patients were included, there were 55 cases of bacteremia or fungemia in the standard-dose group compared with 54 in the low-dose group (P = 0.95). The mean time of initiation of lipids relative to the day of transplant (day 0) was Ϫ3.3 ± 2.4 d among standard-dose and Ϫ3.2 ± 2.9 d among low-dose patients. The mean time of onset of first blood infection after starting lipid was 13.3 ± 8.7 d among standard-dose and 14.1 ± 7.6 d among lowdose patients. The organisms cultured are presented in Table 2 .
When all bacterial or fungal infection sites by 30 d posttransplant were included, there was no association between lipid dose and time to first infection (P = 0.94). Seven patients in the standard-dose and eight in the low-dose group developed a nonblood bacterial or fungal infection before 30 d (Table 3 ).
An additional 3 patients in the low-dose group and 12 in the standard-dose group developed a first bacterial or fungal infection (all blood) when data were evaluated to 60 d posttransplant. Again, no significant difference was found between the two groups in time to first bacteremia or fungemia (P = 0.58) or first bacterial or fungal infection at any site (P = 0.77).
Among patients with blood infections, the effect of lipid treatment on the risk of experiencing subsequent infections was analyzed by a log-rank statistic that considered up to four episodes of bacteremia or fungemia through 60 d posttransplant. When analyzed by intent-to-treat, in the standard-dose group 19, 5, and 3 patients developed second, third, and fourth blood infections, respectively, compared with 13, 3, and 3 patients in the low-dose group. The effect of lipid treatment on the rate of multiple infections was not significant (P = 0.36).
Essential fatty acid status
Essential fatty acids were assayed to determine the incidence of deficiency in the two lipid groups. Data are presented only for patients for whom plasma had been analyzed at the time of the interim analysis: 70 patients in the standard-dose and 86 patients in the low-dose group at 20 d posttransplant and 7 patients in the lowdose group at 40 d posttransplant. Two patients in the low-dose group had a triene:tetraene > 0.2 (values were 0.30 and 0.24). None of the patients who were still in the study and receiving low lipid at 40 d showed biochemical evidence of essential fatty acid deficiency.
Serum glucose and engraftment
An association between hyperglycemia and lipid dose could potentially confound the relation between lipid dose and infection. To examine this relation, the mean daily serum glucose concentration was calculated from the time of initiation of lipid to the endpoints of treatment failure, hospital discharge, death, or 30 d posttransplant. In patients with a blood infection, mean serum glucose was calculated from the time of initiation of lipid to 1 d before the infection, because infection may elevate serum glucose. The values were then classified as normal, < 6.7 mmol/L (< 120 mg/dL); moderately elevated, 6.7-11.1 mmol/L (120-200 mg/dL); or elevated, > 11.1 mmol/L (> 200 mg/dL). Among standard-dose patients, the serum glucose concentrations of 35% were classified as normal, 58% as moderately elevated, and 7% as elevated whereas among low-dose patients, 29% were normal, 63% were moderately elevated, and 8% were elevated. A Cox regression analysis of the association between lipid dose and time to first bacteremia or fungemia to 30 d adjusted for categories of serum glucose (normal, moderately elevated, or elevated) was essentially unchanged from the unadjusted value.
Engraftment occurred in 224 patients (93%) in the standarddose group and 227 (94%) in the low-dose group. In these patients, there was no significant association between lipid group and time to engraftment by the log-rank test (P = 0.20). The mean time posttransplant to engraftment in the standard-dose group was 23.0 ± 8.5 d and in the low-dose group was 22.3 ± 6.7 d. 
Graft-versus-host disease, relapse, and survival
Among patients undergoing allogeneic marrow transplantation, 149 (77%) developed acute GVHD grades II-IV in the standard-dose group compared with 148 (75%) in the low-dose group. A log-rank test of this association between lipid group and time to acute GVHD (grades II-IV) censored for 80 d posttransplant, death, relapse, and treatment failure indicated that there was no association (P = 0.30). Time to relapse by 150 d posttransplant did not differ between the groups (P = 0.82). There were 25 patients in the standard-dose and 27 patients in the low-dose group who relapsed by this time.
In the low-dose group, 37 patients died by 60 d posttransplant compared with 32 in the standard-dose group. When examined as time to early death (60 d), there was no significant difference between lipid groups (P = 0.55). Likewise, there was no significant difference in time to death by 150 d posttransplant with 72 patients in the low-dose group and 79 in the standard-dose group dying by this time (P = 0.48).
DISCUSSION
We did not find a significant association between intravenous lipid dose and bacterial and fungal infections when patients undergoing allogeneic or autologous bone marrow transplantation were provided moderate amounts of a safflower-based 20% lipid emulsion compared with minimal amounts to prevent essential fatty acid deficiency as part of the nutrition support regimen. That the two groups were comparable in terms of infection risk is suggested by the equivalent distribution of relevant clinical variables otherwise not controlled for in the adaptive randomization scheme, including age, diagnosis, type of transplant, environmental isolation technique, time of engraftment, and serum glucose status. Our results are in contrast with preliminary findings from an observational study also at our institution in which 373 participants of an infection-prevention study showed an increased risk of infection with cumulative doses of the same intravenous lipid by using a time-dependent analysis (7). The findings also differ from those described in neonates, to whom the immature immune system of marrow graft recipients may be likened. In a case-control study conducted by Freeman et al (6) in a neonatal intensive care unit, a strong association between the intravenous administration of lipid emulsions and the occurrence of coagulase-negative staphylococcus bacteremia was found in 38 cases compared with 76 controls studied. The odds ratio associated with exposure to lipid among the neonates was 5.8. A large proportion of the cases of bacteremia in the marrow transplant patients reported here were likewise infections with coagulase-negative staphylococcus. Because both treatment groups in our study received lipids, it could be that any exposure to lipids predisposes immunosuppressed patients to bacteremia of a nosocomial origin. However, if a difference exists in bacteremia rates related to an increased exposure to lipid, we should have been able to detect such a difference with our large study population.
Prospective human studies of lipid-free compared with lipidcontaining intravenous nutrition support regimens that have used clinical infection as an outcome measure are limited. In a study of 40 surgical patients with gastrointestinal cancer, no difference in infection rates was detected, but the investigators failed to report the actual rate and the nature of any infectious complications (21) . In a second smaller study, also of surgical patients with gastrointestinal cancer, an 80% incidence of infection occurred in both groups, although the severity of sepsis was asserted to be lower in patients receiving lipid (22) . The lack of clear definitions of infection outcome and the small sample sizes of these studies, as well as the potential dissimilarity between surgical cancer patients and patients with hematologic cancers undergoing marrow grafting, limit any comparisons that can be made about infections and intravenous lipid between these studies and the data reported here.
Our study results are distinguished by a sample size of sufficient power to detect meaningful differences in blood infections. The overall blood infection rate was close to the predicted rate of 25%. By 30 d posttransplant, 23% and 22% in the standard-and low-dose treatment groups, respectively, experienced a bacteremia or fungemia. The rates were lower than expected in part because of the low rates of fungemia, 3.8% and 2.9% in the standard-and low-dose treatment groups, respectively. These low rates reflect a change in clinical practice midway through the study to provide fluconazole prophylaxis to all patients. Fluconazole has been found to reduce fungal infections significantly in marrow transplantation from 7% to < 2% (23) .
There were several clinical concerns about providing less lipid energy than the standard, including the risks of essential fatty acid deficiency, increased hyperglycemia, and a higher incidence of GVHD. Essential fatty acid deficiency has long been associated with immunosuppression as summarized by Sardesai (24) and more recently with bacterial translocation across the gut (25) . The linoleic acid requirement in normal humans is estimated to be 1-2% of total daily energy. We designed an extra margin of safety by providing 3-4% of energy as linoleic acid. Two patients in the low-dose group showed early signs of essential fatty acid deficiency, yet among seven patients assigned to the low-dose group, no biochemical evidence of deficiency was evident 40 d posttransplant. It is likely that individual requirements differ and a small percentage of transplant patients receiving minimal amounts of intravenous lipid will be at risk for deficiency.
Hyperglycemia has been associated with infection in patients with diabetes (26) as well as glycosylation of immunoglobulin G and in vitro impairment of complement fixation (27) . There was no evidence that patients in the low-dose group had higher serum glucose concentrations. However, there were three treatment failures in the low-dose group due to the inability to meet their energy needs almost exclusively with dextrose, suggesting that a small percentage of marrow transplant patients require > 6-8% lipid energy to meet estimated total energy needs.
The final concern with the use of less lipid was the potential to enhance T cell production of interleukin 2 and possibly stimulate GVHD. Pharmacologic doses of the lipid emulsion Intralipid (Kabi Vitrum, Stockholm) have been shown to inhibit interleukin 2 response by T cells in vitro (28) , which may be mediated through increased prostaglandin E 2 synthesis (29) . In a murine model, the graft-versus-host reaction of spleen cells injected into irradiated mice was suppressed in those animals fed a linoleic acid-enriched diet (30) . Our analysis of time to development of acute GVHD would not suggest that an association exists between a low-dose lipid infusion and clinically significant disease.
In conclusion, there was no evidence that moderate doses of a safflower-based intravenous lipid emulsion were associated with the incidence of bacterial or fungal infections in patients undergoing bone marrow transplantation while receiving TPN. The data appear to agree with Klein and Miles's (31) conclusion from reviewing the literature that adverse complications associated with lipid emulsions occur only at rapid infusion rates (> 0.11 g ؒ kg Ϫ1 ؒ h Ϫ1 ). In the absence of any other data showing improved infection outcomes with the use of alternate nutritional strategies, such as medium-chain triacylglycerol-based emulsions, intravenous lipids may be provided to patients undergoing bone marrow transplantation in a manner that is most medically effective. Nutrition support regimens may consider clinical circumstances requiring proportionately more lipid (eg, to reduce carbohydrate load in patients with excessive insulin requirements) or less lipid (eg, in patients with hyperlipidemia) without concern for infection risk. 
